Krystal Biotech, Inc. Common Stock
KRYSKrystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for dermatological and rare diseases. Established with the goal of advancing genetic medicine, it utilizes a proprietary viral vector platform to deliver gene therapies with the potential to treat conditions that have limited treatment options. The company's approach aims to provide targeted, durable treatments for patients suffering from various skin disorders and other genetic conditions.
Company News
Krystal Biotech reported preliminary 4Q 2025 VYJUVEK net revenue of $106-107 million and full-year 2025 revenue of $388-389 million. The company outlined an ambitious strategic vision to become a global leader in rare disease with plans to launch at least four marketed medicines by 2030, treating over 10,000 patients. The company maintains a stro...
S Squared Technology increased its Ambarella position by 35,000 shares (worth $4.8 million) in November, bringing total holdings to $12.7 million. The purchase preceded Ambarella's late-November earnings report, which triggered a 20% stock decline despite record revenue growth of 31% YoY and raised full-year guidance to 38%. The fund's timing sug...
Connecticut-based fund Braidwell established a new $50.8 million stake in Acadia Pharmaceuticals, representing 2.1% of its reportable U.S. equity assets, as the company shows strong quarterly performance and potential for growth in neurological disorder treatments.
Soleno Therapeutics achieved its first profitable quarter with $66 million in revenue, attracting a significant $86.7 million investment from Connecticut-based fund Braidwell, which acquired 1.3 million shares in the biotechnology company.
Krystal Biotech will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, with CEO Krish S. Krishnan hosting a fireside chat and investor meetings. The company has generated $97.8 million in Q3 VYJUVEK revenue and launched the product in multiple countries.
